Skip N2 Metastasis in Pulmonary Adenocarcinoma: Good Prognosis Similar to N1 Disease

被引:13
|
作者
Wang, Lin [1 ]
Ye, Guanzhi [1 ]
Xue, Liang [1 ]
Zhan, Cheng [1 ]
Gu, Jie [1 ]
Xi, Junjie [1 ]
Lin, Zongwu [1 ]
Jiang, Wei [1 ]
Ge, Di [1 ]
Wang, Qun [1 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China
关键词
Lymph node metastasis; N1; disease; N2; Pathological subtype; pN sub-classification; RESPIRATORY SOCIETY CLASSIFICATION; LYMPH-NODE INVOLVEMENT; LUNG ADENOCARCINOMA; INTERNATIONAL ASSOCIATION; IASLC/ATS/ERS CLASSIFICATION; CANCER; RECURRENCE; SURVIVAL; SUBTYPES; RESECTION;
D O I
10.1016/j.cllc.2020.02.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We analyzed the prognosis of lung adenocarcinoma to elucidate the influence of skip N2 metastasis. Skip N2 disease has a similar prognosis to N1 disease and is significantly better than that of non-skip N2 disease. Skip N2 has a prognostic advantage in patients with the acinar-predominant subtype. Pathological subtypes of lung adenocarcinoma may influence subgroup of patients with lymph node metastasis. Introduction: The prognostic effect and mechanism of skip N2 lung cancer remain unclear. Our study aimed to elucidate the influence of skip N2 on overall survival (OS) and disease-free survival (DFS) compared with N1 and non-skip N2 in patients with lung adenocarcinoma. Patients and Methods: Patients with lung adenocarcinoma and lymph node involvement between May 2011 and December 2015 were retrospectively analyzed. The outcomes of skip N2 patients were compared with N1 and non-skip N2 patients. Prognosis was further investigated according to the N status in different adenocarcinoma subtypes. Univariate and multivariate analyses were carried out to define independent risk factors for OS and DFS. Results: A total of 456 patients with lung adenocarcinoma, 169 with N1 disease, 81 with skip N2 disease, and 206 with non-skip N2 disease, were enrolled in this study. All tumors were invasive adenocarcinoma, and the predominant subtypes were acinar in 252, papillary in 42, solid in 119, micropapillary in 20, and invasive mucinous adenocarcinoma in 23 patients. The DFS and OS of N1 and skip N2 diseases were similar and significantly better than those of patients with non-skip N2 disease. The prognosis according to lymph node status was significantly different in acinar-predominant subtypes in terms of both OS and DFS. Conclusions: Skip N2 disease has a similar prognosis to N1 disease and is significantly better than that of non-skip N2 disease in relation to OS and DFS. Skip N2 has a prognostic advantage in patients with the acinar-predominant subtype. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:E423 / E434
页数:12
相关论文
共 50 条
  • [21] Prognostic Impact of Cancer-involved Lymph Node Ratio in Resected NSCLC Differ between 'N1' or 'N2' Disease
    Liang, Wenhua
    He, Jianxing
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S285 - S285
  • [22] Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma Novel Prognostic Implications of Combined N1 and N2 Nodal Involvement Based on Experience in 529 Patients
    Sugarbaker, David J.
    Richards, William G.
    Bueno, Raphael
    ANNALS OF SURGERY, 2014, 260 (04) : 577 - 582
  • [23] Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: "N1" versus "N2" TAN
    Fridlender, Zvi G.
    Sun, Jing
    Kim, Samuel
    Kapoor, Veena
    Cheng, Guanjun
    Ling, Leona
    Worthen, G. Scott
    Albelda, Steven M.
    CANCER CELL, 2009, 16 (03) : 183 - 194
  • [24] Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment
    Stamatis, Georgios
    Mueller, Stefanie
    Weinreich, Gerhard
    Schwarz, Birte
    Eberhardt, Wilfried
    Pottgen, Christoph
    Aigner, Clemens
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2022, 61 (02) : 269 - 276
  • [25] Clinical stage IA non-small cell lung cancer with occult pathologic N1 and N2 disease after segmentectomy: does a completion lobectomy justify?
    Luo, Xun
    Hayanga, Jeremiah William Awori
    Mehaffey, James Hunter
    Lamb, Jason
    Campbell, Stuart
    Reddy, Shalini
    Badhwar, Vinay
    Toker, Alper
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2024, 66 (05)
  • [26] Mediastinoscopic Assessment of N2 Disease and Optimisation of Surgical Treatment of N2 Disease in NSCLC
    Karimundackal, G.
    Patil, V.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S858 - S858
  • [27] Prognostic impact of extranodal extension in patients with pN1–N2 lung adenocarcinoma
    Kotaro Nomura
    Keiju Aokage
    Tokiko Nakai
    Shingo Sakashita
    Tomohiro Miyoshi
    Kenta Tane
    Joji Samejima
    Kenji Suzuki
    Masahiro Tsuboi
    Genichiro Ishii
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 3699 - 3707
  • [28] Presence of micropapillary and solid patterns are associated with nodal upstaging and unfavorable prognosis among patient with cT1N0M0 lung adenocarcinoma: a large-scale analysis
    Yuan, Yonggang
    Ma, Ge
    Zhang, YaQi
    Chen, Haiquan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (04) : 743 - 749
  • [29] Carboxypeptidase N2 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma
    Xu, Ting
    Zhang, Zhe
    Chen, Hongqiang
    Cai, Ruili
    Yang, Qian
    Liu, Qi
    Fan, Yahan
    Liu, Wenbin
    Yao, Chunyan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Clinicopathologic correlates of postoperative N1 or N2 nodal upstaging in non-small cell lung cancer
    Moon, Youngkyu
    Lee, Kyo Young
    Kim, Kyung Soo
    Park, Jae Kil
    JOURNAL OF THORACIC DISEASE, 2016, 8 (01) : 79 - 85